Article Details

AstraZeneca, FibroGen hit another roxadustat setback as FDA panel calls for more safety data

Retrieved on: 2021-07-15 21:33:45

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca, FibroGen hit another roxadustat setback as FDA panel calls for more safety data. View article details on hiswai:

Excerpt

AstraZeneca and its roxadustat partner FibroGen headed into a high-stakes FDA expert meeting this week after receiving tough safety questions about ...

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up